risedronic acid has been researched along with Osseous Paget's Disease in 48 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although etidronate is effective, risedronate offers a shorter duration of therapy, better and longer-lasting remission, significant reductions in pain, and provides additional remission in subjects who exhibited an incomplete response to previous etidronate treatment." | 5.09 | A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. ( Axelrod, DW; Bekker, PJ; Brown, JP; Hoseyni, MS; Miller, PD; Siris, ES, 1999) |
| "Studies of risedronate were obtained from the MEDLINE database (1966 to the present) of references using risedronate, risedronic acid, osteoporosis, and human subject as keywords." | 4.81 | Risedronate: a clinical review. ( Crandall, C, 2001) |
| "5 mg once daily was well tolerated by patients with PDB, even though the dosage was seven times higher than that approved for the treatment of osteoporosis in Japan (2." | 2.75 | Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone. ( Hashimoto, J; Takata, S; Yoh, K; Yoshimura, N, 2010) |
| "Zoledronic acid (ZOL) is a potent bisphosphonate that produces a rapid and complete control of the increased bone turnover of Paget's disease." | 2.73 | Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. ( Brown, JP; Curiel, MD; Devogelaer, JP; Eriksen, EF; Fashola, T; Fraser, WD; Hooper, M; Hosking, D; Lyles, K; Miller, P; Pak, J; Reid, IR; Saidi, Y; Su, G; Zelenakas, K, 2007) |
| "Zoledronic acid was associated with a shorter median time to a first therapeutic response (64 vs." | 2.71 | Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. ( Brown, JP; Fraser, W; Hosking, D; Luchi, M; Lyles, K; Mesenbrink, P; Miller, P; Pak, J; Reid, IR; Richardson, P; Saidi, Y; Su, G; Zelenakas, K, 2005) |
| " The data show that there is a dose-response with risedronate: patients who received 30 mg oral risedronate for 28 days benefited most, with a mean percentage decrease in AP excess of 72." | 2.69 | Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study. ( Bekker, PJ; Brown, JP; Hosking, DJ; Johnson, TD; Johnston, CC; Reginster, J; Ryan, WG; Ste-Marie, L, 1999) |
| " Six BPs are currently approved by the US Food and Drug Administration (FDA) for the treatment of Paget disease, and each has unique characteristics, such as response rates and requirements for dosage and administration, relevant to clinical outcome." | 2.44 | Paget disease of bone: therapeutic options. ( Silverman, SL, 2008) |
| " Intravenous pamidronate is efficacious and has long been available, but its use is hindered by an impractical recommended dosing regimen of 30 mg IV over 4 h for three consecutive days." | 2.44 | A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. ( Abelson, A, 2008) |
| " Whenever the initial dose failed to produce remission, the dosage was increased to twice a week the respective dose." | 1.51 | Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting. ( Abu Tailakh, M; Liel, Y, 2019) |
| "Paget disease of bone is the most common metabolic bone disease after osteoporosis, affecting 2-4% of adults over 55 years of age." | 1.38 | Paget disease of bone - an update. ( Britton, C; Walsh, J, 2012) |
| "Pamidronate treatment (60 mg/day for 3 days) was repeated in patients without evidence of PDB remission at day 120." | 1.32 | Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. ( Mossetti, G; Nunziata, V; Rendina, D; Sorrentino, M; Viceconti, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (25.00) | 18.2507 |
| 2000's | 29 (60.42) | 29.6817 |
| 2010's | 6 (12.50) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Ralston, SH | 1 |
| Liel, Y | 2 |
| Abu Tailakh, M | 1 |
| Ohara, M | 1 |
| Imanishi, Y | 1 |
| Nagata, Y | 1 |
| Ishii, A | 1 |
| Kobayashi, I | 1 |
| Mori, K | 1 |
| Ito, M | 1 |
| Miki, T | 1 |
| Nishizawa, Y | 1 |
| Inaba, M | 1 |
| Silverman, SL | 1 |
| Torres, J | 1 |
| Tamimi, F | 1 |
| Garcia, I | 1 |
| Herrero, A | 1 |
| Rivera, B | 1 |
| Sobrino, JA | 1 |
| Hernández, G | 1 |
| Yoh, K | 1 |
| Takata, S | 2 |
| Yoshimura, N | 1 |
| Hashimoto, J | 1 |
| Woo, JH | 1 |
| Kim, S | 1 |
| Choi, SJ | 1 |
| Lee, YH | 1 |
| Ji, JD | 1 |
| Song, GG | 1 |
| Britton, C | 1 |
| Walsh, J | 1 |
| Nishida, Y | 1 |
| Yamada, Y | 1 |
| Tsukushi, S | 1 |
| Sugiura, H | 1 |
| Urakawa, H | 1 |
| Ishiguro, N | 1 |
| Fournier, P | 1 |
| Boissier, S | 1 |
| Filleur, S | 1 |
| Guglielmi, J | 1 |
| Cabon, F | 1 |
| Colombel, M | 1 |
| Clézardin, P | 1 |
| Rendina, D | 3 |
| Mossetti, G | 3 |
| Viceconti, R | 2 |
| Sorrentino, M | 1 |
| Nunziata, V | 2 |
| De Filippo, G | 2 |
| Di Domenico, G | 1 |
| Cioffi, M | 1 |
| Postiglione, L | 1 |
| Brixen, KT | 1 |
| Abrahamsen, B | 1 |
| Kassem, MS | 1 |
| Mosekilde, L | 1 |
| Orcel, P | 1 |
| Rousière, M | 1 |
| Barrera, BA | 1 |
| Wilton, L | 1 |
| Harris, S | 1 |
| Shakir, SA | 1 |
| Reid, IR | 2 |
| Miller, P | 2 |
| Lyles, K | 2 |
| Fraser, W | 1 |
| Brown, JP | 8 |
| Saidi, Y | 2 |
| Mesenbrink, P | 1 |
| Su, G | 2 |
| Pak, J | 2 |
| Zelenakas, K | 2 |
| Luchi, M | 1 |
| Richardson, P | 1 |
| Hosking, D | 3 |
| Füessl, HS | 1 |
| Whitson, HE | 1 |
| Lobaugh, B | 1 |
| Lyles, KW | 1 |
| Krane, SM | 1 |
| Fraser, WD | 1 |
| Curiel, MD | 1 |
| Devogelaer, JP | 1 |
| Hooper, M | 1 |
| Fashola, T | 1 |
| Eriksen, EF | 1 |
| Zillikens, MC | 1 |
| Ginai, AZ | 1 |
| Pols, HA | 1 |
| Abelson, A | 1 |
| Olmos Martínez, JM | 1 |
| Hernández Hernández, JL | 1 |
| Martínez García, J | 1 |
| González Macías, J | 1 |
| Kylstra, JW | 1 |
| Bekker, PJ | 5 |
| Axelrod, DW | 2 |
| Siris, ES | 3 |
| Altman, RD | 2 |
| Singer, FR | 3 |
| Hosking, DJ | 4 |
| Eusebio, RA | 4 |
| Chines, AA | 3 |
| Patel, S | 1 |
| Pearson, D | 1 |
| Bhallah, A | 1 |
| Maslanka, W | 1 |
| White, DA | 1 |
| Clemens, TL | 1 |
| Johnston, CC | 2 |
| Lang, R | 1 |
| McClung, MR | 1 |
| Mallette, LE | 1 |
| Miller, PD | 3 |
| Ryan, WG | 2 |
| Tucci, JR | 1 |
| Ste-Marie, L | 1 |
| Reginster, J | 1 |
| Johnson, TD | 1 |
| Hoseyni, MS | 1 |
| Hussar, DA | 1 |
| Myers, WR | 1 |
| Ritter-Hrncirik, C | 1 |
| Hayes, CW | 1 |
| Crandall, C | 1 |
| Drake, WM | 1 |
| Kendler, DL | 1 |
| Dunn, CJ | 1 |
| Goa, KL | 1 |
| Chapurlat, RD | 1 |
| Delmas, PD | 1 |
| Umland, EM | 1 |
| Boyce, EG | 1 |
| Bannwarth, B | 1 |
| Shiraki, M | 1 |
14 reviews available for risedronic acid and Osseous Paget's Disease
| Article | Year |
|---|---|
Paget disease of bone: therapeutic options.
Topics: Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Humans; | 2008 |
[Pharmacological treatment of osteitis deformans (Paget's bone disease)].
Topics: Alendronate; Analgesics, Non-Narcotic; Antimetabolites; Calcitonin; Clodronic Acid; Diphosphonates; | 2005 |
[Paget's disease and its therapeutic management].
Topics: Administration, Oral; Alkaline Phosphatase; Biomarkers; Diphosphonates; Etidronic Acid; Follow-Up St | 2005 |
Pharmacological therapy of Paget's and other metabolic bone diseases.
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Etidron | 2006 |
[Therapeutic effects of risedronate on Paget's disease of bone].
Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Etidronic Acid; Humans; Male; Oste | 2006 |
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Humans; | 2008 |
Prediction and assessment of the response of Paget's disease to bisphosphonate treatment.
Topics: Alkaline Phosphatase; Bone Resorption; Diphosphonates; Etidronic Acid; Half-Life; Humans; Osteitis D | 1999 |
The use of risedronate in Paget's disease.
Topics: Alkaline Phosphatase; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Fibrous Dysplasia, | 1999 |
Risedronate: a clinical review.
Topics: Animals; Bone and Bones; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Etidronic Acid; F | 2001 |
Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.
Topics: Alendronate; Alkaline Phosphatase; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; | 2001 |
Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Topics: Bone and Bones; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Half-Life; Humans; I | 2001 |
Risedronate: clinical usage.
Topics: Bone Density; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Ostei | 2001 |
Risedronate: a new oral bisphosphonate.
Topics: Administration, Oral; Alendronate; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; | 2001 |
[Risedronate: clinical usage].
Topics: Bone Density; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fractures; Fractures, Stress; H | 2002 |
9 trials available for risedronic acid and Osseous Paget's Disease
| Article | Year |
|---|---|
Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Ma | 2010 |
Midterm outcome of risedronate therapy for patients with Paget's disease of bone in the central part of Japan.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agen | 2013 |
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Remodeling; Dipho | 2005 |
Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
Topics: Administration, Oral; Adult; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relatio | 2006 |
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Co | 2007 |
Risedronate in Paget's disease: preliminary results of a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Middle Age | 1994 |
Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Calcium Chan | 1998 |
Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Calcium Channel Blockers; Consumer Product Safety; Do | 1999 |
A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Bone and Bones; Calcium Channel Blockers; Double-B | 1999 |
25 other studies available for risedronic acid and Osseous Paget's Disease
| Article | Year |
|---|---|
Bisphosphonates in the management of Paget's disease.
Topics: Alendronate; Diphosphonates; Humans; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2020 |
Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Humans; Male; | 2019 |
Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Asian People; Biomarkers; Bone and Bones; Bone Den | 2015 |
Dental implants in a patient with Paget disease under bisphosphonate treatment: a case report.
Topics: Administration, Oral; Bone Density Conservation Agents; Dental Implantation, Endosseous; Dental Pros | 2009 |
Diagnosis of Paget's disease of the pelvis using F-18 FDG PET/CT.
Topics: Asymptomatic Diseases; Bone Density Conservation Agents; Diagnosis, Differential; Etidronic Acid; Fe | 2010 |
Paget disease of bone - an update.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Ac | 2012 |
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Topics: Angiogenesis Inhibitors; Animals; Bone and Bones; Cell Division; Cells, Cultured; Clodronic Acid; Di | 2002 |
Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Calcitriol; Clodronic Acid; Diphosphonates; Drug Toleran | 2004 |
Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.
Topics: Aged; Etidronic Acid; Female; Glycoproteins; Humans; Interleukin-6; Male; Middle Aged; Osteitis Defo | 2005 |
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents; | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alendronate; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedu | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Diphosphonates; Disease Progression; Etidronic Acid; Hum | 2005 |
[Optimizing therapy in Paget disease].
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; E | 2005 |
Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
Topics: Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Hy | 2006 |
[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
Topics: Aged; Aged, 80 and over; Alendronate; Biological Availability; Bone Density Conservation Agents; Dip | 2006 |
[A young woman with headaches and skull anomalies: a long road to the diagnosis 'Paget's disease'].
Topics: Adult; Alkaline Phosphatase; Bone Density Conservation Agents; Diagnosis, Differential; Etidronic Ac | 2006 |
[Radius shaft fracture in a 31-year old man].
Topics: Adult; Bone Density Conservation Agents; Etidronic Acid; Humans; Male; Osteitis Deformans; Radiograp | 2008 |
Paget's disease of bone: reduction of disease activity with oral risedronate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Calcium; Calcium Channel Blocke | 1998 |
Changes in bone mineral density in patients with Paget's disease treated with risedronate.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Bone Remodeling; Calcium Channel Bloc | 1997 |
Risedronate released for Paget's disease.
Topics: Calcium Channel Blockers; Drug Approval; Etidronic Acid; Humans; Osteitis Deformans; Risedronic Acid | 1998 |
Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Calcitriol; Calcium; Calcium Channel Blockers; Creati | 1998 |
Risedronate for Paget's disease of bone.
Topics: Administration, Oral; Aged; Bone Resorption; Calcium Channel Blockers; Clinical Trials as Topic; Dia | 1998 |
New drugs 99, Part III.
Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antibodies, Monoclonal; Antibodies, Monoclona | 1999 |
Improvement of pagetic bone lesions with risedronate treatment: a radiologic study.
Topics: Aged; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteitis Deformans; Radiography; Risedronic | 2000 |
[Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
Topics: Aged; Calcium Channel Blockers; Cortisone; Costs and Cost Analysis; Double-Blind Method; Etidronic A | 2002 |